利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

314 条记录 (耗时 0.084 秒)

    RS7 Antibodies
    72.
    发明申请
    RS7 Antibodies 有权
    RS7抗体

    公开(公告)号：US20100221177A1

    公开(公告)日：2010-09-02

    申请号：US12389503

    申请日：2009-02-20

    申请人： Serengulam V. Govindan ,  Zhengxing Qu ,  Hans J. Hansen ,  David M. Goldenberg

    发明人： Serengulam V. Govindan ,  Zhengxing Qu ,  Hans J. Hansen ,  David M. Goldenberg

    IPC分类号： A61K51/10 ,  C07K16/18 ,  A61K39/395 ,  A61K38/21 ,  A61K49/00 ,  A61K38/20 ,  A61P35/00

    CPC分类号： A61K45/06 ,  A61K39/39558 ,  A61K51/1045 ,  A61K51/1051 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3015 ,  C07K2317/21 ,  C07K2317/24

    摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    摘要翻译： 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。

    METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER
    77.
    发明申请
    METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER 有权
    免疫学方法和组合物，检测炎症和免疫缺陷性疾病，感染性疾病，病理性血管生成和癌症

    公开(公告)号：US20080241145A1

    公开(公告)日：2008-10-02

    申请号：US11929279

    申请日：2007-10-30

    申请人： David M. Goldenberg ,  Hans J. Hansen

    发明人： David M. Goldenberg ,  Hans J. Hansen

    IPC分类号： A61K39/395 ,  C07K16/18

    CPC分类号： A61K39/3955 ,  A61K31/513 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/4866 ,  A61K39/40 ,  A61K45/06 ,  A61K49/0002 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1203 ,  C07K16/24 ,  C07K16/241 ,  C07K16/248 ,  C07K16/2803 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/734

    摘要： A multispecific antagonist is disclosed that reacts specifically with at least two different targets. The targets are (A) proinflammatory effectors of the innate immune system, (B) coagulation factors, (C) complement factors and complement regulatory proteins, and (D) targets specifically associated with an inflammatory or immune-dysregulatory disorder or with a pathologic angiogenesis or cancer, wherein this latter target is not (A), (B) or (C). At least one of the targets is (C), and when the multispecific antagonist comprises a single multispecific antibody, then CD74 is excluded as a target of said antagonist. When the multispecific antagonist comprises a combination of separate antibodies, combinations are excluded where one of said antibodies targets a B-cell antigen and the other antibody targets a T-cell, plasma cell, macrophage or inflammatory cytokine and combinations are also excluded where one of said antibodies targets CD20 and the other antibody targets C3b or CD40.

    摘要翻译： 公开了与至少两个不同靶物特异性反应的多特异性拮抗剂。 目标是（A）先天免疫系统的促炎效应物，（B）凝血因子，（C）补体因子和补体调节蛋白，以及（D）与炎症或免疫调节障碍或病理血管发生特异性相关的靶标 或癌症，其中后一靶标不是（A），（B）或（C）。 至少一个目标是（C），并且当多特异性拮抗剂包含单个多特异性抗体时，则排除CD74作为所述拮抗剂的靶标。 当多特异性拮抗剂包含单独的抗体的组合时，除了其中一种所述抗体靶向B细胞抗原并且另一种抗体靶向T细胞，浆细胞，巨噬细胞或炎性细胞因子的组合之外，并且组合也被排除在其中之一 所述抗体靶向CD20，其他抗体靶标为C3b或CD40。